Dr. Felgar completed a residency in Anatomic and Clinical Pathology at the Hospital of the University of Pennsylvania in 1996, and a fellowship in Hematopathology at Vanderbilt University Medical Center in 1998. He is board-certified in Anatomic and Clinical Pathology, with subspecialty certification in Hematology (American Board of Pathology). As Director of the Flow Cytometry and Bone Marrow Laboratory, his clinical activities include the evaluation and implementation of new equipment and test methods. Recently, the laboratory has seen a 40-50% increase in the number of test requests, including lymphocyte subset testing, lymphoma/leukemia analyses, and CD34+ stem cell analyses (for stem cell and bone marrow transplant patients). Dr. Felgar's clinical responsibilities include the signout of bone marrow biopsies and aspirates, lymphnodes and tissue workups for lymphoma, and flow cytometry lymphoma/leukemia evaluations.

Segel GB, Woodlock TJ, Xu J, Li L, Felgar RE, Ryan DH, Lichtman MA, Wang N. Early gene activation in chronic leukemic B lymphocytes induced toward a plasma cell phenotype. Blood Cells Mol Dis. 2003 May-Jun;30(3):277-87.

Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003 Feb;48(2):455-9.

Felgar RE. Murine lymphomas: are there counterparts in the Revised European-American classification of lymphoid neoplasms? Leuk Res 2001 Nov;25(11):1029-30 PubMed Publication List

Felgar RE. Minimal residual disease detection by flow cytometry: Can it serve as a predictor of future relapse? Leuk Res 2001 May;25(5):409-11 PubMed Publication List

Przybylski GK, Wu H, Macon WR, Finan J, Leonard DG, Felgar RE, DiGiuseppe JA, Nowell PC, Swerdlow SH, Kadin ME, Wasik MA, Salhany KE. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn 2000 Feb;2(1):11-9 PubMed Publication List

Felgar RE. CD38: an 'orphan' protein that may be finding a home? Leuk Res 2000 Feb;24(2):161-2 PubMed Publication List

Felgar RE, Salhany KE, Macon WR, Pietra GG, Kinney MC. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum Pathol 1999 Feb;30(2):228-36 PubMed Publication List

Felgar RE, Steward KR, Cousar JB, Macon WR. T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. Am J Pathol 1998 Dec;153(6):1707-15 PubMed Publication List

ASCP CheckSample Program:

Felgar RE. Acute mylogenous leukemia, minimally differentiated (AML-M0): Clinical and diagnostic features. ASCP Check Sample Program: Clinical Hematology Series (in press).

Liang S and Felgar RE. Acute megakaryoblastic leukemia: Clinical and diagnostic Features. ASCP Check Sample Program: Clinical Hematology Series (in press).

Liman AK and Felgar RE. Plasmablastic lymphoma: Morphologic and diagnostic features. ASCP Check Sample Program: Clinical Hematology Series 7:27-39, 2001.

Deng AC and Felgar RE. T-prolymphocytic leukemia: Diagnosis and clinicopathologic features. ASCP Check Sample Program: Hematopathology Series 6:75-89, 2000.